Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

Website: orthocell.com.au

Employees: 20 - 49

HQ:

Location: Murdoch, WAU, AU

Revenue: 2.5 - 5 Million

Orthocell is a leading biotechnology company that specializes in developing innovative cellular therapies for the treatment of various diseases. If you're looking for contact information for Orthocell, you've come to the right place. At ConnectPlex.ai, we provide accurate and up-to-date contact information for millions of companies around the world, including Orthocell. Our extensive database contains contact details for key decision-makers, department heads, and other important personnel, making it easy for you to get in touch with the right people at Orthocell. Whether you're looking to collaborate on a research project, inquire about their products, or explore business opportunities, our contact information for Orthocell will help you connect with the right people. At ConnectPlex.ai, we're committed to providing high-quality contact information that is both accurate and relevant, so you can be sure that you're getting the best possible leads. Our keyword-rich content is optimized for search engines, ensuring that our page ranks high for search terms like 'contact details for Orthocell'. So why wait? Connect with Orthocell today and take the first step towards building a successful business relationship.

Orthocell is a cutting-edge regenerative medicine company based in Murdoch, Australia. With a focus on regenerating mobility for patients, the company has developed a range of innovative products for the repair of tendon, cartilage, and soft tissue injuries. Orthocell's product portfolio includes TGA-licensed cell therapies, such as Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. In addition to its cell therapies, Orthocell has developed Celgro®, a collagen medical device that facilitates tissue repair and healing in various orthopaedic, reconstructive, and surgical applications. The company is readying Celgro® for first regulatory approvals, marking a significant milestone in its mission to transform the lives of patients. Led by a team of experienced executives, including Nic Telford, Alexander McHenry, and Paul Anderson, Orthocell is poised for continued growth and success in the rapidly evolving field of regenerative medicine. With a strong focus on research and development, the company is committed to advancing the science of soft tissue repair and regeneration, and improving patient outcomes. Orthocell's innovative products and commitment to excellence have earned the company recognition and accolades within the industry. The company's dedication to improving the lives of patients through regenerative medicine is truly inspiring, and we look forward to seeing the impact of their work in the years to come.

Orthocell is a company that helps people recover from injuries that affect their mobility. They create products that can repair damaged tendons, cartilage, and soft tissue. They have two products that are already approved by the government, called Ortho-ATI® and Ortho-ACI®. These products use the patient's own cells to repair the damage. They also have a product called Celgro®, which is a medical device made of collagen that helps the body heal itself. Celgro® is almost ready to be approved by the government.